
BMS-212122
CAS No. 194213-64-4
BMS-212122( —— )
Catalog No. M34524 CAS No. 194213-64-4
BMS-212122 (UNII-0Z473OO6GB) is a potent inhibitor of microsomal triglyceride transfer protein (MTP) and has shown hypolipidemic effects in animal studies.BMS-212122 significantly reduced lipid content and monocyte-derived (CD68+) cells in atherosclerotic plaques.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 532 | Get Quote |
![]() ![]() |
5MG | 787 | Get Quote |
![]() ![]() |
10MG | 1074 | Get Quote |
![]() ![]() |
25MG | 1463 | Get Quote |
![]() ![]() |
50MG | 1822 | Get Quote |
![]() ![]() |
100MG | 2250 | Get Quote |
![]() ![]() |
500MG | 4410 | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameBMS-212122
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-212122 (UNII-0Z473OO6GB) is a potent inhibitor of microsomal triglyceride transfer protein (MTP) and has shown hypolipidemic effects in animal studies.BMS-212122 significantly reduced lipid content and monocyte-derived (CD68+) cells in atherosclerotic plaques.
-
DescriptionBMS-212122 (UNII-0Z473OO6GB) is a potent inhibitor of microsomal triglyceride transfer protein (MTP) and has shown hypolipidemic effects in animal studies.BMS-212122 significantly reduced lipid content and monocyte-derived (CD68+) cells in atherosclerotic plaques.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetCETP
-
RecptorCETP
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number194213-64-4
-
Formula Weight754.76
-
Molecular FormulaC43H36F6N4O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(NCC(F)(F)F)(=O)C1(CCCCN2C=3C(N=C2C)=C(NC(=O)C4=C(C=CC=C4)C5=CC=C(C(F)(F)F)C=C5)C(C)=CC3)C=6C(C=7C1=CC=CC7)=CC=CC6
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog



related products
-
BMS-212122
BMS-212122 (UNII-0Z473OO6GB) is a potent inhibitor of microsomal triglyceride transfer protein (MTP) and has shown hypolipidemic effects in animal studies.BMS-212122 significantly reduced lipid content and monocyte-derived (CD68+) cells in atherosclerotic plaques.
-
CKD-519
CKD-519 (Rocacetrapib, CKD519) is a potent, selective cholesteryl ester transfer protein (CETP) inhibitor, inhibits the CETP-mediated transfer of cholesteryl ester in human serum with IC50 of 2.3 nM.
-
SR17018
SR17018 is an mu-opioid-receptor (MOR) agonist, binding with GTPγS, with an EC50 of 97 nM.